These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30362868)

  • 21. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.
    Chen YW; Muralidhar V; Mahal BA; Nezolosky MD; Beard CJ; Choueiri TK; Hoffman KE; Martin NE; Orio PF; Sweeney CJ; Feng FY; Trinh QD; Nguyen PL
    Brachytherapy; 2016; 15(6):695-700. PubMed ID: 27528590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.
    Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Xie L; Meadows E; Danella J; Cher ML
    BMC Urol; 2018 Jun; 18(1):55. PubMed ID: 29866100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural History of Nonmetastatic Prostate Cancer Managed With Watchful Waiting.
    Ventimiglia E; Gedeborg R; Styrke J; Robinson D; Stattin P; Garmo H
    JAMA Netw Open; 2024 Jun; 7(6):e2414599. PubMed ID: 38833251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in quality of care for men with early-stage prostate cancer.
    Spencer BA; Miller DC; Litwin MS; Ritchey JD; Stewart AK; Dunn RL; Gay EG; Sandler HM; Wei JT
    J Clin Oncol; 2008 Aug; 26(22):3735-42. PubMed ID: 18669460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
    Ladjevardi S; Sandblom G; Berglund A; Varenhorst E
    Eur Urol; 2010 Apr; 57(4):631-8. PubMed ID: 19299069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of data quality in the National Prostate Cancer Register of Sweden.
    Tomic K; Sandin F; Wigertz A; Robinson D; Lambe M; Stattin P
    Eur J Cancer; 2015 Jan; 51(1):101-11. PubMed ID: 25465187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden.
    Tomic K; Westerberg M; Robinson D; Garmo H; Stattin P
    Acta Oncol; 2016 Dec; 55(12):1461-1466. PubMed ID: 27749139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.
    Bandini M; Nazzani S; Marchioni M; Preisser F; Tian Z; Moschini M; Abdollah F; Suardi N; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Feb; 17(1):72-78.e4. PubMed ID: 30342845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
    Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
    Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
    Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
    Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan.
    Wu CC; Lin CH; Chiang HS; Tang MJ
    Int J Equity Health; 2018 Jun; 17(1):79. PubMed ID: 29903010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    BJU Int; 2018 Feb; 121(2):209-216. PubMed ID: 28418195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT.
    Mihalcik SA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Eur Urol Focus; 2018 Jan; 4(1):64-67. PubMed ID: 28753752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cancers before and after prostate cancer diagnosis.
    Van Hemelrijck M; Drevin L; Holmberg L; Garmo H; Adolfsson J; Stattin P
    Cancer; 2012 Dec; 118(24):6207-16. PubMed ID: 22674346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capture rate and representativity of The National Prostate Cancer Register of Sweden.
    Tomic K; Berglund A; Robinson D; Hjälm-Eriksson M; Carlsson S; Lambe M; Stattin P
    Acta Oncol; 2015 Feb; 54(2):158-63. PubMed ID: 25034349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
    Heidenreich A; Pfister D; Brehmer B; Porres D
    Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.